Anlotinib is new oral inhibitor that targets various receptor tyrosine kinases (RTKs) to treat osteosarcoma, especially after traditional chemotherapy is ineffective or during advanced tumour stages.12, 17, 33. The gene discussed is NTRK1; the disease is neoplasm.